Drug Profile
Research programme: anaemia therapies - Transition Therapeutics
Alternative Names: Anemia therapies - Transition Therapeutics; Hypoxia inducible factor prolyl hydroxylase inhibitors - Transition TherapeuticsLatest Information Update: 24 Aug 2010
Price :
$50
*
At a glance
- Originator Transition Therapeutics
- Class
- Mechanism of Action Mixed function oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 05 Jun 2008 Preclinical development is ongoing
- 15 Mar 2006 Preclinical trials in Anaemia in Canada (unspecified route)